BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Prostate Cancer readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Prostate Cancer\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05168618-2031@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05168618)
DESCRIPTION:Cabozantinib\, phase 2\, Prostate Cancer.\nStudy: Cabozantinib 
 and Atezolizumab for the Treatment of Metastatic Castration-Resistant Pros
 tate Cancer\nEstimated primary completion: November 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05168618
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03951831-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT03951831)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: REGN2
 810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive 
 Prostate Cancer\nEstimated primary completion: November 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03951831
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06267729-11145@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:AZD0754: Phase 1/2 readout est. (NCT06267729)
DESCRIPTION:AZD0754\, phase 1/2\, Prostate Cancer.\nStudy: Study of AZD0754
  in Participants With Metastatic Prostate Cancer\nEstimated primary comple
 tion: 24 November 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/azd0754#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06267729
URL:https://assetmemo.bio/drug/azd0754#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05546268-2661@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:MRT-2359: Phase 1/2 readout est. (NCT05546268)
DESCRIPTION:MRT-2359\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of Oral MRT-2359 in Selected Cancer Patients\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mr
 t-2359#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05546268
URL:https://assetmemo.bio/drug/mrt-2359#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06568094-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06568094)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Prostate Cancer.\nStudy: A S
 tudy of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With 
 Advanced Prostate Cancer\nEstimated primary completion: December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06568094
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06568094-11086@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-5041: Phase 1/2 readout est. (NCT06568094)
DESCRIPTION:HRS-5041\, phase 1/2\, Prostate Cancer.\nStudy: A Study of HRS-
 5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Pro
 state Cancer\nEstimated primary completion: December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/hrs-5041#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06568094
URL:https://assetmemo.bio/drug/hrs-5041#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03258320-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT03258320)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Prostate Cancer.\nStudy: A R
 andomised Trial of Cabazitaxel\, Docetaxel\, Mitoxantrone or Satraplatin (
 CDMS) Plus Surgery for Prostate Cancer Patients\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 ocetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03258320
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03903835-7646@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capivasertib: Phase 3 readout est. (NCT03903835)
DESCRIPTION:Capivasertib\, phase 3\, Prostate Cancer.\nStudy: ProBio: A Bio
 marker Driven Study in Patients With Metastatic Prostate Cancer\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/capivasertib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03903835
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03903835-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT03903835)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: ProBio: A Biomarker Driven Study in Patients Wi
 th Metastatic Prostate Cancer\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03903835
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06480110-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06480110)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: Ebastine in Combination With Docetaxel as a T
 reatment for Castration-resistant Metastatic Prostate Cancer\nEstimated pr
 imary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06480110
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combinat
 ion of Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04140526
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04633252-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT04633252)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Prostate Cancer.\nStudy: A P
 hase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With 
 Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration 
 Resistant Prostate Cancer\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04633252
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05873192-2243@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Talazoparib: Phase 2 readout est. (NCT05873192)
DESCRIPTION:Talazoparib\, phase 2\, Prostate Cancer.\nStudy: Presurgical Ph
 ase II Study of Talazoparib in Combination With Enzalutamide in Prostate C
 ancer\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/talazoparib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05873192
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05406999-11066@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rezvilutamide: Phase 2 readout est. (NCT05406999)
DESCRIPTION:Rezvilutamide\, phase 2\, Prostate Cancer.\nStudy: Neoadjuvant 
 Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Canc
 er\nEstimated primary completion: 31 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/rezvilutamide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05406999
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04253262-2060@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Rucaparib: Phase 1/2 readout est. (NCT04253262)
DESCRIPTION:Rucaparib\, phase 1/2\, Metastatic Castration-Resistant Prostat
 e Cancer.\nStudy: A Study of Copanlisib Combined With Rucaparib in Patient
 s With Metastatic Castration-resistant Prostate Cancer\nEstimated primary 
 completion: January 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/rucaparib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04253262
URL:https://assetmemo.bio/drug/rucaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04015622-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT04015622)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: PROstate Cancer TReatment Optimization Via Anal
 ysis of Circulating Tumour DNA\nEstimated primary completion: 31 January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04015622
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06738745-11086@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:HRS-5041: Phase 2 readout est. (NCT06738745)
DESCRIPTION:HRS-5041\, phase 2\, Prostate Cancer.\nStudy: Study of HRS-2189
  Combined HRS-5041 in Prostate Cancer\nEstimated primary completion: 31 Ja
 nuary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-5041#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0673
 8745
URL:https://assetmemo.bio/drug/hrs-5041#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03866382-2031@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT03866382)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Testing 
 the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) Wi
 th One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tum
 ors\nEstimated primary completion: 28 February 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03866382
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03456843-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT03456843)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: Thera
 peutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Dia
 gnosed Metastatic Prostate Cancer\nEstimated primary completion: March 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03456843
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05753566-11066@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rezvilutamide: Phase 2 readout est. (NCT05753566)
DESCRIPTION:Rezvilutamide\, phase 2\, Prostate Cancer.\nStudy: Rezvilutamid
 e in Patients With Biochemical Recurrence After Radical Prostatectomy for 
 Prostate Cancer\nEstimated primary completion: March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/rezvilutamide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05753566
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241416-11066@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rezvilutamide: Phase 3 readout est. (NCT07241416)
DESCRIPTION:Rezvilutamide\, phase 3\, Prostate Cancer.\nStudy: A Phase III 
 Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensit
 ive Prostate Cancer\nEstimated primary completion: March 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/rezvilutamide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07241416
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04455750-2060@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Rucaparib: Phase 3 readout est. (NCT04455750)
DESCRIPTION:Rucaparib\, phase 3\, Prostate Cancer.\nStudy: A Clinical Study
  Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With M
 etastatic Prostate Cancer That Has Become Resistant To Testosterone-Depriv
 ation Therapy\nEstimated primary completion: 15 March 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rucaparib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04455750
URL:https://assetmemo.bio/drug/rucaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03574571-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT03574571)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Prostate Cancer.\nStudy: A Stu
 dy to Test Radium-223 With Docetaxel in Patients With Prostate Cancer\nEst
 imated primary completion: 1 April 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03574571
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06909825-2028@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Olaparib: Phase 2 readout est. (NCT06909825)
DESCRIPTION:Olaparib\, phase 2\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Me
 tastatic Castration-Resistant Prostate Cancer (mCRPC)\nEstimated primary c
 ompletion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06909825
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07711314-11066@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rezvilutamide: Phase 2 readout est. (NCT07711314)
DESCRIPTION:Rezvilutamide\, phase 2\, Prostate Cancer.\nStudy: Adjuvant Rez
 vilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostat
 ectomy\nEstimated primary completion: May 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/rezvilutamide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07711314
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644068-2090@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Saruparib: Phase 1/2 readout est. (NCT04644068)
DESCRIPTION:Saruparib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer A
 gents in Patients With Advanced Solid Malignancies\nEstimated primary comp
 letion: 28 May 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 saruparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04644068
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04812366-7646@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Capivasertib: Phase 2 readout est. (NCT04812366)
DESCRIPTION:Capivasertib\, phase 2\, Prostate Cancer.\nStudy: Genomic Bioma
 rker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate 
 Cancer\nEstimated primary completion: 1 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/capivasertib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04812366
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04812366-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT04812366)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: Genom
 ic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized P
 rostate Cancer\nEstimated primary completion: 1 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04812366
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05189457-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05189457)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: First
  Strike\, Second Strike Therapies for High Risk Metastatic Castration Sens
 itive Prostate Cancer\nEstimated primary completion: 15 July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05189457
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04734730-2243@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270823
DTEND;VALUE=DATE:20270824
SUMMARY:Talazoparib: Phase 2 readout est. (NCT04734730)
DESCRIPTION:Talazoparib\, phase 2\, Prostate Cancer.\nStudy: Talazoparib Wi
 th Androgen Deprivation Therapy and Abiraterone for the Treatment of Castr
 ation Sensitive Prostate Cancer\nEstimated primary completion: 23 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/talazoparib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04734730
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04038502-2028@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Olaparib: Phase 2 readout est. (NCT04038502)
DESCRIPTION:Olaparib\, phase 2\, Prostate Cancer.\nStudy: Carboplatin or Ol
 aparib for BRcA Deficient Prostate Cancer\nEstimated primary completion: 3
 1 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olapar
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4038502
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120491-2090@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Saruparib: Phase 3 readout est. (NCT06120491)
DESCRIPTION:Saruparib\, phase 3\, Prostate Cancer.\nStudy: Saruparib (AZD53
 05) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer
  Receiving Physician's Choice New Hormonal Agents\nEstimated primary compl
 etion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/saruparib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06120491
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745361-2661@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:MRT-2359: Phase 2 readout est. (NCT07745361)
DESCRIPTION:MRT-2359\, phase 2\, Prostate Cancer.\nStudy: Study of Oral MRT
 -2359 With Apalutamide in Prostate Cancer\nEstimated primary completion: O
 ctober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mrt-2359
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 45361
URL:https://assetmemo.bio/drug/mrt-2359#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02861573-2028@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271022
DTEND;VALUE=DATE:20271023
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT02861573)
DESCRIPTION:Olaparib\, phase 1/2\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: Study of Pembrolizumab (MK-3475) Combination Therapies in
  Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
 \nEstimated primary completion: 22 October 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT02861573
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02861573-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271022
DTEND;VALUE=DATE:20271023
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT02861573)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: Study of Pembrolizumab (MK-3475) Combination 
 Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/
 KEYNOTE-365)\nEstimated primary completion: 22 October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT02861573
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407283-11066@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rezvilutamide: Phase 1/2 readout est. (NCT07407283)
DESCRIPTION:Rezvilutamide\, phase 1/2\, Prostate Cancer.\nStudy: A Clinical
  Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Canc
 er\nEstimated primary completion: November 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/rezvilutamide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07407283
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407283-11086@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:HRS-5041: Phase 1/2 readout est. (NCT07407283)
DESCRIPTION:HRS-5041\, phase 1/2\, Prostate Cancer.\nStudy: A Clinical Stud
 y of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer\nE
 stimated primary completion: November 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/hrs-5041#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07407283
URL:https://assetmemo.bio/drug/hrs-5041#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407283-11101@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:SHR-4394: Phase 1/2 readout est. (NCT07407283)
DESCRIPTION:SHR-4394\, phase 1/2\, Prostate Cancer.\nStudy: A Clinical Stud
 y of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer\nE
 stimated primary completion: November 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/shr-4394#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07407283
URL:https://assetmemo.bio/drug/shr-4394#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03972657-11310@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Nezastomig: Phase 1/2 readout est. (NCT03972657)
DESCRIPTION:Nezastomig\, phase 1/2\, Prostate Cancer.\nStudy: A Trial to Fi
 nd Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in 
 Combination With Cemiplimab for Adult Participants With Metastatic Castrat
 ion-Resistant Prostate Cancer and Other Tumors\nEstimated primary completi
 on: 15 November 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nezastomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT03972657
URL:https://assetmemo.bio/drug/nezastomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225946-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271119
DTEND;VALUE=DATE:20271120
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT07225946)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: A Study of Pasritamig With Docetaxel Versus Doc
 etaxel in Participants With Metastatic Castration-Resistant Prostate Cance
 r\nEstimated primary completion: 19 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07225946
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06520345-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06520345)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: The Study of 177Lu-TLX591 Plus SOC Versus SOC A
 lone in Patients With mCRPC (ProstACT Global)\nEstimated primary completio
 n: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doc
 etaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06520345
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05568550-2028@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271202
DTEND;VALUE=DATE:20271203
SUMMARY:Olaparib: Phase 2 readout est. (NCT05568550)
DESCRIPTION:Olaparib\, phase 2\, Prostate Cancer.\nStudy: Pembro With Radia
 tion With or Without Olaparib\nEstimated primary completion: 2 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05568550
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06582628-2243@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Talazoparib: Phase 2 readout est. (NCT06582628)
DESCRIPTION:Talazoparib\, phase 2\, Prostate Cancer.\nStudy: Talazoparib Pl
 us Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Can
 cer\nEstimated primary completion: 31 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/talazoparib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06582628
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07906717-11219@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:JNJ-101556143: Phase 3 readout est. (NCT07906717)
DESCRIPTION:JNJ-101556143\, phase 3\, Prostate Cancer.\nStudy: A Study of J
 NJ-101556143 With Best Supportive Care in Participants With Metastatic Pro
 state Cancer\nEstimated primary completion: 14 February 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/jnj-101556143#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07906717
URL:https://assetmemo.bio/drug/jnj-101556143#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06305832-11066@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rezvilutamide: Phase 2 readout est. (NCT06305832)
DESCRIPTION:Rezvilutamide\, phase 2\, Prostate Cancer.\nStudy: Salvage Radi
 otherapy Combined With Androgen Deprivation Therapy (ADT) With or Without 
 Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Pro
 statectomy for Prostate Cancer\nEstimated primary completion: March 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/rezvilutamide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06305832
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07723248-10910@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rinzimetostat: Phase 3 readout est. (NCT07723248)
DESCRIPTION:Rinzimetostat\, phase 3\, Prostate Cancer.\nStudy: A Study to L
 earn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients W
 ith mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-
 1)\nEstimated primary completion: March 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/rinzimetostat#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07723248
URL:https://assetmemo.bio/drug/rinzimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03682289-2028@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olaparib: Phase 2 readout est. (NCT03682289)
DESCRIPTION:Olaparib\, phase 2\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: Ceralasertib (AZD6738) Alone and in Combination With Olapar
 ib or Durvalumab in Patients With Solid Tumors\nEstimated primary completi
 on: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ol
 aparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03682289
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07795177-11066@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Rezvilutamide: Phase 2 readout est. (NCT07795177)
DESCRIPTION:Rezvilutamide\, phase 2\, Prostate Cancer.\nStudy: A Prospectiv
 e Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combin
 ed With Second-generation Novel Hormonal Agents in Metastatic Hormone-sens
 itive Prostate Cancer.\nEstimated primary completion: 30 April 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/rezvilutamide#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07795177
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780670-11245@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280627
DTEND;VALUE=DATE:20280628
SUMMARY:225Ac-PSMA-617: Phase 2/3 readout est. (NCT06780670)
DESCRIPTION:225Ac-PSMA-617\, phase 2/3\, Prostate Cancer.\nStudy: Open-labe
 l Study Comparing AAA817 Versus Standard of Care in the Treatment of Previ
 ously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or
  After [177Lu]Lu-PSMA Targeted Therapy\nEstimated primary completion: 27 J
 une 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/225ac-psma-
 617#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06780670
URL:https://assetmemo.bio/drug/225ac-psma-617#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06085664-11310@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nezastomig: Phase 1/2 readout est. (NCT06085664)
DESCRIPTION:Nezastomig\, phase 1/2\, Prostate Cancer.\nStudy: A Pilot Presu
 rgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk\, L
 ocalized Prostate Cancer Followed by Radical Prostatectomy\nEstimated prim
 ary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/nezastomig#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06085664
URL:https://assetmemo.bio/drug/nezastomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226986-11246@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:AMO959: Phase 1/2 readout est. (NCT07226986)
DESCRIPTION:AMO959\, phase 1/2\, Prostate Cancer.\nStudy: A Phase Ib/II Ope
 n-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA61
 7) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
 \nEstimated primary completion: 10 July 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/amo959#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07226986
URL:https://assetmemo.bio/drug/amo959#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06800313-11219@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280817
DTEND;VALUE=DATE:20280818
SUMMARY:JNJ-101556143: Phase 1/2 readout est. (NCT06800313)
DESCRIPTION:JNJ-101556143\, phase 1/2\, Prostate Cancer.\nStudy: Study of H
 LD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer\nEstim
 ated primary completion: 17 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/jnj-101556143#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06800313
URL:https://assetmemo.bio/drug/jnj-101556143#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07164443-11223@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280818
DTEND;VALUE=DATE:20280819
SUMMARY:JNJ-87189401: Phase 3 readout est. (NCT07164443)
DESCRIPTION:JNJ-87189401\, phase 3\, Prostate Cancer.\nStudy: A Study of Pa
 sritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metasta
 tic Castration-resistant Prostate Cancer (mCRPC)\nEstimated primary comple
 tion: 18 August 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /jnj-87189401#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07164443
URL:https://assetmemo.bio/drug/jnj-87189401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855277-11245@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280929
DTEND;VALUE=DATE:20280930
SUMMARY:225Ac-PSMA-617: Phase 3 readout est. (NCT06855277)
DESCRIPTION:225Ac-PSMA-617\, phase 3\, Prostate Cancer.\nStudy: Study Compa
 ring AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-p
 ositive mCRPC\nEstimated primary completion: 29 September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/225ac-psma-617#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06855277
URL:https://assetmemo.bio/drug/225ac-psma-617#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05593497-7646@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Capivasertib: Phase 2 readout est. (NCT05593497)
DESCRIPTION:Capivasertib\, phase 2\, Prostate Cancer.\nStudy: A Single-Arm 
 Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide
  and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib
 ) for High-Risk Localized Prostate Cancer With PTEN Loss\nEstimated primar
 y completion: 31 October 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/capivasertib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05593497
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230106-11066@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rezvilutamide: Phase 2 readout est. (NCT07230106)
DESCRIPTION:Rezvilutamide\, phase 2\, Prostate Cancer.\nStudy: A Study of S
 HR3680\, HS-20093 and SHR2554 in Subjects With Prostate Cancer\nEstimated 
 primary completion: December 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/rezvilutamide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07230106
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07641855-2028@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Olaparib: Phase 2/3 readout est. (NCT07641855)
DESCRIPTION:Olaparib\, phase 2/3\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: A Study of BL-B01D1 Combination Therapy in Patients With 
 Metastatic Castration-resistant Prostate Cancer\nEstimated primary complet
 ion: December 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 laparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07641855
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07730580-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07730580)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: Study
  of XNW5004 Tablets in Advanced Prostate Cancer\nEstimated primary complet
 ion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07730580
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06734130-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06734130)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: Adapt
 ive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive 
 Prostate Cancer\nEstimated primary completion: January 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06734130
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353386-2028@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT06353386)
DESCRIPTION:Olaparib\, phase 1/2\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684
 )-Based Treatment Combinations or Opevesostat Alone in Participants With M
 etastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)\nEsti
 mated primary completion: 15 January 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06353386
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353386-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06353386)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: Substudy 01A: Safety and Efficacy of Opevesos
 tat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Partici
 pants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-568
 4-01A)\nEstimated primary completion: 15 January 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06353386
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181161-11144@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290118
DTEND;VALUE=DATE:20290119
SUMMARY:AZD0516: Phase 1/2 readout est. (NCT07181161)
DESCRIPTION:AZD0516\, phase 1/2\, Prostate Cancer.\nStudy: Study of AZD0516
  as Monotherapy and in Combination in Participants With Metastatic Prostat
 e Cancer\nEstimated primary completion: 18 January 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/azd0516#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07181161
URL:https://assetmemo.bio/drug/azd0516#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844383-2243@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Talazoparib: Phase 2 readout est. (NCT06844383)
DESCRIPTION:Talazoparib\, phase 2\, Metastatic Castration-Resistant Prostat
 e Cancer.\nStudy: A Study of Talazoparib With or Without Enzalutamide in P
 eople With Prostate Cancer Who Have Previously Received Abiraterone Acetat
 e or Darolutamide\nEstimated primary completion: March 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/talazoparib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06844383
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192614-11148@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290329
DTEND;VALUE=DATE:20290330
SUMMARY:AZD6621: Phase 1/2 readout est. (NCT07192614)
DESCRIPTION:AZD6621\, phase 1/2\, Prostate Cancer.\nStudy: A Study to Learn
  How Safe AZD6621 is\, How Well it Works\, and How it Moves Throughout the
  Body Over Time\, in Adult Male Participants With Metastatic Prostate Canc
 er\nEstimated primary completion: 29 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/azd6621#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07192614
URL:https://assetmemo.bio/drug/azd6621#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07832292-11219@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290517
DTEND;VALUE=DATE:20290518
SUMMARY:JNJ-101556143: Phase 2 readout est. (NCT07832292)
DESCRIPTION:JNJ-101556143\, phase 2\, Prostate Cancer.\nStudy: A Study of J
 NJ-101556143 in Participants With Metastatic Prostate Cancer\nEstimated pr
 imary completion: 17 May 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/jnj-101556143#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07832292
URL:https://assetmemo.bio/drug/jnj-101556143#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07907653-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07907653)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: Deute
 nzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Be
 fore Surgery for High-Risk Localized or Locally Advanced Prostate Cancer\n
 Estimated primary completion: July 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07907653
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07698535-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290705
DTEND;VALUE=DATE:20290706
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07698535)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: Measuring Circulating Tumor Deoxyribonucleic Ac
 id Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation 
 in Patients With Metastatic Castration-Resistant Prostate Cancer\, DYNAMO 
 Trial\nEstimated primary completion: 5 July 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07698535
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05125016-11300@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20300328
DTEND;VALUE=DATE:20300329
SUMMARY:Olsutamig: Phase 1/2 readout est. (NCT05125016)
DESCRIPTION:Olsutamig\, phase 1/2\, Prostate Cancer.\nStudy: A Trial to Fin
 d Out if REGN4336 is Safe and How Well it Works Alone and in Combination W
 ith REGN5678 for Adult Participants With Advanced Prostate Cancer\nEstimat
 ed primary completion: 28 March 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/olsutamig#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05125016
URL:https://assetmemo.bio/drug/olsutamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05125016-11310@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20300328
DTEND;VALUE=DATE:20300329
SUMMARY:Nezastomig: Phase 1/2 readout est. (NCT05125016)
DESCRIPTION:Nezastomig\, phase 1/2\, Prostate Cancer.\nStudy: A Trial to Fi
 nd Out if REGN4336 is Safe and How Well it Works Alone and in Combination 
 With REGN5678 for Adult Participants With Advanced Prostate Cancer\nEstima
 ted primary completion: 28 March 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nezastomig#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05125016
URL:https://assetmemo.bio/drug/nezastomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07333066-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT07333066)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Prostate Cancer.\nStudy: Phase
  III Randomized International Open Label Clinical Trial of Treatment Inten
 sification With Docetaxel Plus Apalutamide in Patients With Metastatic Hor
 mone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response Aft
 er Initial Treatment With Apalutamide: REINFORCE Trial.\nEstimated primary
  completion: 31 March 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07333066
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-2031@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Cabozantinib\, phase 3\, Hepatocellular Carcinoma.\nStudy: Long
 -Term Extension Study for Participants Previously Enrolled in an Exelixis-
 Sponsored Study\nEstimated primary completion: 31 May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06282588-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT06282588)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Prostate Cancer.\nStudy: Tre
 atment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and 
 Molecular Tracers\nEstimated primary completion: 31 July 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06282588
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594106-11300@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20301027
DTEND;VALUE=DATE:20301028
SUMMARY:Olsutamig: Phase 1/2 readout est. (NCT07594106)
DESCRIPTION:Olsutamig\, phase 1/2\, Prostate Cancer.\nStudy: REGN15505 (PSM
 Ax4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in
  Adult Patients With Metastatic Castration-Resistant Prostate Cancer and C
 lear Cell Renal Cell Carcinoma\nEstimated primary completion: 27 October 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/olsutamig#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07594106
URL:https://assetmemo.bio/drug/olsutamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594106-11301@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20301027
DTEND;VALUE=DATE:20301028
SUMMARY:REGN15505: Phase 1/2 readout est. (NCT07594106)
DESCRIPTION:REGN15505\, phase 1/2\, Prostate Cancer.\nStudy: REGN15505 (PSM
 Ax4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in
  Adult Patients With Metastatic Castration-Resistant Prostate Cancer and C
 lear Cell Renal Cell Carcinoma\nEstimated primary completion: 27 October 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/regn15505#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07594106
URL:https://assetmemo.bio/drug/regn15505#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06592924-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20310314
DTEND;VALUE=DATE:20310315
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06592924)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Prostate Cancer.\nStudy: Docet
 axel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic C
 astration Sensitive Prostate Cancer and Suboptimal PSA Response\nEstimated
  primary completion: 14 March 2031. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06592924
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06320067-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06320067)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Prostate Cancer.\nStudy: A Ran
 domised Controlled Platform Trial Testing Treatments in Metastatic Hormone
  Sensitive Prostate Cancer\nEstimated primary completion: April 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06320067
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05367440-2090@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20310411
DTEND;VALUE=DATE:20310412
SUMMARY:Saruparib: Phase 1/2 readout est. (NCT05367440)
DESCRIPTION:Saruparib\, phase 1/2\, Prostate Cancer.\nStudy: Study of AZD53
 05 When Given in Combination With New Hormonal Agents in Patients With Met
 astatic Prostate Cancer\nEstimated primary completion: 11 April 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/saruparib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05367440
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07711002-2090@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20310530
DTEND;VALUE=DATE:20310531
SUMMARY:Saruparib: Phase 3 readout est. (NCT07711002)
DESCRIPTION:Saruparib\, phase 3\, Prostate Cancer.\nStudy: Saruparib in Com
 bination With Physician's Choice of ARPI in Patients With mHSPC Previously
  Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression 
 and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)\nEstimated primary completion: 30 May 
 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/saruparib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07711002
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850921-11310@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20310728
DTEND;VALUE=DATE:20310729
SUMMARY:Nezastomig: Phase 1/2 readout est. (NCT07850921)
DESCRIPTION:Nezastomig\, phase 1/2\, Prostate Cancer.\nStudy: REGN21353 Alo
 ne or in Combination With Nezastomig for Metastatic Castration-Resistant P
 rostate Cancer in Adult Participants\nEstimated primary completion: 28 Jul
 y 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/nezastomig#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078509
 21
URL:https://assetmemo.bio/drug/nezastomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931340-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20311111
DTEND;VALUE=DATE:20311112
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06931340)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Prostate Cancer.\nStudy: Testi
 ng the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormon
 al Therapy and Apalutamide) for Metastatic Prostate Cancer\, ASPIRE Trial\
 nEstimated primary completion: 11 November 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06931340
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07730151-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07730151)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: Effic
 acy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuv
 ant Therapy for Locally Advanced Prostate Cancer.\nEstimated primary compl
 etion: 31 December 2031. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07730151
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005154-11062@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Abiraterone decanoate: Phase 2 readout est. (NCT07005154)
DESCRIPTION:Abiraterone decanoate\, phase 2\, Prostate Cancer.\nStudy: A Ph
 ase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prosta
 te Cancer\nEstimated primary completion: 31 May 2032. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/abiraterone-decanoate#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07005154
URL:https://assetmemo.bio/drug/abiraterone-decanoate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645326-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20320831
DTEND;VALUE=DATE:20320901
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07645326)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: RISK-
 ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)\nEs
 timated primary completion: August 2032. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07645326
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952803-2090@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Saruparib: Phase 3 readout est. (NCT06952803)
DESCRIPTION:Saruparib\, phase 3\, Prostate Cancer.\nStudy: A Study of Metas
 tases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT i
 n Men With High-risk Prostate Cancer With a BRCA Mutation\nEstimated prima
 ry completion: 31 March 2033. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/saruparib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06952803
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667400-9029@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20361001
DTEND;VALUE=DATE:20361002
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT07667400)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: Docetaxel and SX-682 in Recurrent/Metastatic 
 Head and Neck Squamous Cell Carcinoma\, Salivary Gland Carcinoma\, and Adv
 anced Prostate Cancer\nEstimated primary completion: 1 October 2036. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07667400
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
